Segantii Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Segantii Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50	Closed	-$6K	–	671
2021 Q4	$6K	Sell	50 -70,340	-100%	-$8.48M	﹤0.01%	599
2021 Q3	$8.85M	Buy	70,390 +51,486	+272%	+$6.63M	0.29%	63
2021 Q2	$2.56M	Sell	18,904 -4,854	-20%	-$638K	0.07%	135
2021 Q1	$3.22M	Buy	+23,758	New	+$3.56M	0.14%	89

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Segantii Capital Management's XBI Position: Q1 2022 in Review

Segantii Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 50 shares — an estimated $6K sold.

Segantii Capital Management first reported a position in XBI in Q1 2021 and held it in 4 quarters. The position peaked at $8.85M in Q3 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Segantii Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Segantii Capital Management sold 50 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $6K.
Segantii Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 4 quarters.
Segantii Capital Management's State Street SPDR S&P Biotech ETF position peaked at $8.85M in Q3 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Segantii Capital Management's 13F filing for Q1 2022, filed 26 Apr 2022.